Detail akcie Ovid Theraptcs Rg online

Business Summary: Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Ovid Therapeutics Inc revenues increased from $490K to $6.5M. Net loss increased 58% to $27.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects SGA balancing increase of 37% to $7.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.24 to -$0.38.